U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07587242) titled 'A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping' on May 08.
Brief Summary: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Muscular Dystrophies
Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)
Muscular Disorders, Atrophic
Muscular Disease
Musculo...